BLU
BELLUS Health Inc.
Set alert
14.75 0.00 0.00%
14.74 Day range 14.75
52-week range unavailable
- Open
- 14.74
- Prev close
- 14.75
- Mkt cap
- 1.87B
- Vol
- 2.84M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 14.74
- High
- 14.75
- Forward P/E
- -12.39
- Beta
- -0.28
- Short ratio
- 2.61
- Inst. own
- 90.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2023
- 50-d avg
- 14.59
- 200-d avg
- 10.22
- 1y target
- 16.05
Key statistics
- Market cap
- 1.87B
- Enterprise value
- 1.56B
- Trailing P/E
- 0.00
- Forward P/E
- -12.39
- PEG ratio
- 0.00
- Price / sales
- 124613.92
- Price / book
- 5.06
- EPS (TTM)
- -0.73
- Beta
- -0.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 15.00K
- Revenue growth
- -25.00%
- Free cash flow
- -54.76M
- Total cash
- 312.99M
- Total debt
- 1.20M
- Return on equity
- -26.76%
- Shares outstanding
- 126.81M
- Short % of float
- 0.00%
- 50-day average
- 14.59
- 200-day average
- 10.22
Analyst view
Consensus: buy
Buy
Price target (mean) 16.05 +8.9% upside
Now 14.75
- Target (low)
- 14.75
- Target (mean)
- 16.05
- Target (high)
- 20.00
Next earnings
Aug 9, 2023
Expected Aug 9, 2023. Consensus EPS estimate -0.24.
Financials — quick view
BLU Revenue — quarterly 0
BLU Net income — quarterly -25.06M
BLU EPS — quarterly -0.20
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 9, 2023 | Jun 1, 2023 | -0.24 | — | — | — |
| May 12, 2023 | Mar 1, 2023 | -0.20 | — | — | — |
| Mar 21, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.18 | — | — | — |
| Aug 10, 2022 | Jun 1, 2022 | -0.17 | — | — | — |
| May 11, 2022 | Mar 1, 2022 | -0.18 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 15, 2023 | RBC Capital | reit | Sector Perform | Sector Perform |
| Apr 19, 2023 | RBC Capital | down | Outperform | Sector Perform |
| Apr 19, 2023 | Jefferies | down | Buy | Hold |
| Apr 18, 2023 | Evercore ISI Group | down | Outperform | In-Line |
| Mar 22, 2023 | RBC Capital | reit | — | Outperform |
| Mar 22, 2023 | HC Wainwright & Co. | reit | — | Buy |
About BELLUS Health Inc.
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- bellushealth.com
News
- BLUENERGIES ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT OF UNITS FOR GROSS PROCEEDS OF C$20.7 MILLION
- Bellus Health shareholders say yes to US$2B GSK takeover
- BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
- Alliance Entertainment Reports Third Quarter and Nine Month Fiscal 2023 Financial Results
- BELLUS Santé inc. convoque une assemblée extraordinaire des actionnaires concernant l’acquisition de la société par GSK
- BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition
- BELLUS Santé annonce ses résultats financiers et faits saillants pour le premier trimestre de 2023
- BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
- BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
- Tommy Hilfiger, Mercedes-AMG PETRONAS Formula One Team e Awake NY lanciano una collaborazione al Grand Prix di Miami
Your note
Sign in to keep a note on BLU — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Bellini (Francesco) | Director of Issuer | Exercise of options | Nov 24, 2022 | 345,077 |
| Bellini (Roberto) | Director of Issuer | Exercise of options | Nov 24, 2022 | 1,010,403 |
| Desjardins, Francois | Senior Officer of Issuer | Acquisition or disposition in the public market | Mar 31, 2022 | 8,333 |
| Garceau, Denis | Senior Officer of Issuer | Acquisition or disposition in the public market | Mar 2, 2022 | 34,934 |
| Matzouranis (Tony) | Senior Officer of Issuer | Acquisition or disposition in the public market | Mar 2, 2022 | 24,391 |
| Naud (Nathalie) | Senior Officer of Issuer | Acquisition or disposition in the public market | Mar 8, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.97% | 12,643,574 | 186.37M | Mar 30, 2023 |
| Goldman Sachs Group Inc | 5.85% | 7,413,933 | 109.28M | Mar 30, 2023 |
| Pictet Asset Management SA | 5.58% | 7,072,143 | 104.24M | Mar 30, 2023 |
| Commodore Capital Lp | 5.19% | 6,579,359 | 96.98M | Mar 30, 2023 |
| Orbimed Advisors LLC. | 4.03% | 5,108,900 | 75.31M | Mar 30, 2023 |
| Perceptive Advisors Llc | 3.91% | 4,952,538 | 73.00M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | 1.28% | 1,621,196 | 23.90M | Feb 27, 2023 |
| iShares NASDAQ Biotechnology ETF | 0.65% | 825,614 | 12.17M | Feb 27, 2023 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 0.46% | 587,700 | 8.66M | Jan 30, 2023 |
| Lord Abbett Securities Trust-Micro-Cap Growth Fund | 0.22% | 282,972 | 4.17M | Jan 30, 2023 |
| John Hancock Global Thematic Opportunities Fd | 0.14% | 178,544 | 2.63M | Feb 27, 2023 |
| EQ Advisors Trust-1290 VT Micro Cap Port | 0.12% | 150,030 | 2.21M | Dec 30, 2022 |